Clinical Trial Update: A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating how rosuvastatin (CRESTOR) affects high-density lipoprotein kinetics in patients with metabolic syndrome; the study has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Metabolic Syndrome

Drugs mentioned

• CRESTOR (Rosuvastatin)

Snippet

Sponsor: AstraZeneca | Conditions: Metabolic Syndrome, Dyslipidemia | Phase 3 | Status: COMPLETED